Back to top
more

Karyopharm Therapeutics (KPTI)

(Delayed Data from NSDQ)

$1.06 USD

1.06
660,655

0.00 (0.00%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.05 -0.01 (-0.94%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for KPTI

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Karyopharm Therapeutics Inc. [KPTI]

Reports for Purchase

Showing records 201 - 220 ( 386 total )

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 201

01/17/2020

Company Report

Pages: 6

XPOVIO Sales Beat, We See Shares as Fully Valued, Downgrade to Neutral

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 202

01/14/2020

Company Report

Pages: 7

Management Provides 4Q19 Estimated Sales; Raising PT by $1 to $37

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 203

01/10/2020

Daily Note

Pages: 62

Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended January 3 2020

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 204

12/23/2019

Daily Note

Pages: 3

Karyopharm Submits NDA for Xpovio in r/r DLBCL

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 205

12/12/2019

Industry Report

Pages: 47

ASH 2019: Hangover: Covered Companies Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 100.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 206

12/09/2019

Industry Report

Pages: 12

ASH 2019: Key Presentations Roundup for Covered Companies Days 1-2

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 207

12/09/2019

Company Report

Pages: 8

A Plethora of Compelling Data at ASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 208

11/15/2019

Daily Note

Pages: 35

2019 Abstract Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 209

11/06/2019

Company Report

Pages: 8

3Q19 Financials; Encouraging Start for XPOVIO Launch, Eyes Ahead to BOSTON

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 210

11/06/2019

Daily Note

Pages: 8

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 211

11/05/2019

Company Report

Pages: 8

3Q19 Earnings; Xpovio Launch Starts Strong; Raising PT to $36 From $32

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 212

10/01/2019

Industry Report

Pages: 16

Biotechnology - Monthly Check-Up: October 2019

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 213

09/17/2019

Company Report

Pages: 8

Royalty Agreement Alleviates Financing Risk, Raising PT

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 214

09/17/2019

Daily Note

Pages: 6

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 215

09/16/2019

Company Report

Pages: 6

Xpovio Presentations at the 17th International Myeloma Workshop

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 216

09/16/2019

Daily Note

Pages: 3

Karyopharm Enters Into Royalty Agreement for up to $150 Million, Cash Runway Now Into Mid-2021

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 217

08/06/2019

Company Report

Pages: 6

2Q19 Results; Xpovio Launch Underway

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 218

08/06/2019

Company Report

Pages: 8

2Q19 Financials Awaiting Additional XPOVIO Launch Visibility in Q3

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 219

08/02/2019

Daily Note

Pages: 10

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 220

07/05/2019

Company Report

Pages: 12

XPOVIO Approved for Refractory Multiple Myeloma Despite FDA Panel

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party